clinical trial · NCT06825494
Clinical Studies for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·phase2·recruiting·n = 194
Advanced Solid TumorLM-108 injection+Penpulimab+ Oxaliplatin+CapecitabineTislelizumab+Oxaliplatin+CapecitabineLM-108 injection 10mg/kg +penpulimabLM-108 injection 600mg + penpulimabenpulimab+ Oxaliplatin+Capecitabine
brief summary
This trial is part of a multicenter, open-label Phase Ib/II clinical study evaluating the efficacy, safety, and tolerability of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors. Phase Ib of Cohort A1 determines the dose of LM-108 in combination with penpulimab + oxaliplatin + capecitabine. Phase II explores the efficacy and safety of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors.
started
Apr 8, 2025
primary completion
Mar 1, 2026
completion
Sep 1, 2026
last updated
Dec 18, 2025
official title
An Open-label Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab + Chemotherapy in Patients With Advanced Solid Tumors - Cohort A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol